

# **FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer**

Jul 24, 2015

---

**Source URL:** <https://qa1.novartis.us/news/media-releases/fda-approves-novartis-drug-odomzo-sonidegib-locally-advanced-basal-cell-carcinoma-labcc-form-skin-cancer-0>

## **List of links present in page**

1. <https://qa1.novartis.us/news/media-releases/fda-approves-novartis-drug-odomzo-sonidegib-locally-advanced-basal-cell-carcinoma-labcc-form-skin-cancer-0>